Anlotinib Retrospective Study for Esophageal Cancer
Sponsor
Feng Wang (Other)
Overall Status
Completed
CT.gov ID
NCT05303740
Collaborator
(none)
300
1
37.9
7.9
Study Details
Study Description
Brief Summary
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Study Type:
Observational
Actual Enrollment
:
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study
Actual Study Start Date
:
Jan 1, 2019
Actual Primary Completion Date
:
Mar 1, 2022
Actual Study Completion Date
:
Mar 1, 2022
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Anlotinib
|
Drug: Anlotinib
This is an observational study.
|
Outcome Measures
Primary Outcome Measures
- PFS [From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months]
Progression Free Survival
Secondary Outcome Measures
- OS [From date of admission until the date of death from any cause, assessed up to 24 months]
Overall Survival
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Esophageal cancer diagnosed pathologically or clinically
-
Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment
Exclusion Criteria:
None
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | China | 450000 |
Sponsors and Collaborators
- Feng Wang
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Feng Wang,
Chief physician,
The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier:
NCT05303740
Other Study ID Numbers:
- L2021-Y348-001
First Posted:
Mar 31, 2022
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: